Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GM508 CultActive is a bicarbonate-buffered, human serum albumin (HSA)-free reagent designed for artificial oocyte activation (AOA) during assisted reproductive technology (ART) procedures, specifically intracytoplasmic sperm injection (ICSI). Developed by Gynemed, its active component is the calcium ionophore A23187 (also known as calcimycin). The reagent works by inducing a transient increase in intracellular calcium concentration within the oocyte, mimicking the physiological calcium oscillations normally triggered by a fertilizing sperm. This process is intended to rescue fertilization failure in cases of male factor infertility, such as globozoospermia or severe oligoasthenoteratozoospermia, where the sperm may be deficient in oocyte-activating factors. While used clinically in IVF procedures, it is often classified as a medical device or laboratory reagent rather than a traditional pharmaceutical.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GM508 CultActive.